BSEBoard Meeting2d ago · 10 Nov 2026, 04:53 pm

Outcome of Board Meeting held on Tuesday i.e. 10th November, 2026.

Oxygenta Pharmaceutical Ltd · 524636

✦ AI SummaryResults

Oxygenta Pharmaceutical Ltd's board meeting on November 10, 2026, considered and approved the un-audited financial results for the quarter and half year ended September 30, 2026, and the limited review report for the quarter ended September 30, 2026.

Analysis Scores

Earnings Impact8/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact9/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Oxygenta Pharmaceutical Ltd - 524636 - Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday I.E. 10Th November, 2026.

Attachments (1)

📄

198020fc-93b8-4895-a033-67662464d07e.pdf

pdf

Download →
View document text
To Date: 10.11.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Outcome of Board Meeting With reference to the subject cited this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Tuesday, 10th November, 2026, at 12:30 p.m. at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and half year ended 30.09.2026. (Attached) 2. Limited Review Report for the quarter ended 30.09.2026. (Attached) The Meeting concluded at 4:00 p.m. This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Mamilla Whole-time Director (DIN: 01998852)